1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Aldeyra Claims Success In Final Phase III For First-In-Class Dry Eye Drug

Both Co-Primary Endpoints Hit In TRANQUILITY-2

 
• By Jessica Merrill

The company plans to submit an NDA for reproxalap for dry eye disease based on the results and hailed the crossover trial design as unique in the therapeutic area.

eye dropper
Aldeyra is developing a new eye drug • Source: Shutterstock

Aldeyra Therapeutics, Inc. believes it has the data it needs to file for US Food and Drug Administration approval of reproxalap for dry eye disease following successful completion of a Phase III study that met co-primary endpoints for ocular redness and tear production, and that the data position reproxalap well to compete in the dry eye market.

The company announced the clinical trial results on 12 July, about six months after its initial Phase III trial, TRANQUILITY,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

More from R&D

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.